Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) was the recipient of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 3,949,802 shares, a growth of 44.5% from the August 15th total of 2,732,938 shares. Based on an average trading volume of 5,999,808 shares, the short-interest ratio is presently 0.7 days. Approximately 17.9% of the shares of the company are short sold.

A number of research firms have recently weighed in on IDXG. ValuEngine raised shares of Interpace Diagnostics Group from a “strong sell” rating to a “sell” rating in a research report on Monday, September 11th. Maxim Group began coverage on shares of Interpace Diagnostics Group in a research report on Tuesday, August 15th. They set a “buy” rating and a $5.00 target price for the company.

An institutional investor recently bought a new position in Interpace Diagnostics Group stock. Susquehanna International Group LLP bought a new stake in shares of Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 718,076 shares of the business services provider’s stock, valued at approximately $646,000. Susquehanna International Group LLP owned about 3.84% of Interpace Diagnostics Group at the end of the most recent quarter. 7.41% of the stock is currently owned by institutional investors.

Interpace Diagnostics Group (IDXG) opened at 1.59 on Tuesday. The company’s market capitalization is $35.24 million. Interpace Diagnostics Group has a 12-month low of $0.07 and a 12-month high of $14.25. The company has a 50-day moving average of $1.25 and a 200 day moving average of $1.72.

Interpace Diagnostics Group (NASDAQ:IDXG) last announced its earnings results on Thursday, August 10th. The business services provider reported ($0.65) EPS for the quarter. Interpace Diagnostics Group had a negative net margin of 37.08% and a negative return on equity of 32.06%. The business had revenue of $3.86 million for the quarter.

WARNING: This piece of content was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

Receive News & Stock Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related stocks with our FREE daily email newsletter.